Results 171 to 180 of about 6,312 (217)
SLC25A20 deficiency in tumor cells compromises mitochondrial LCFA transport, which suppresses FAO and drives compensatory release of palmitic acid‐enriched lipids into the TME. These tumor‐derived palmitic acids are taken up by TANs, promoting ZDHHC18‐catalyzed ARG1 palmitoylation.
Yue Han +8 more
wiley +1 more source
Lactate Signal: Modulator of Cellular Energy Production and Anabolism
Compartmentalized lactate signaling provides a spatial framework for understanding how lactate‐rich states are generated, transported, sensed, and translated into biological outputs. This Review integrates extracellular, cytosolic, mitochondrial‐associated, and nuclear lactate mechanisms to explain how lactate shapes metabolic adaptation, immune ...
Han Wang, Si‐Yuan Yang, Wei Xu
wiley +1 more source
Fluorinated β‐glucan/pectin nanogels enable colon‐targeted oral delivery of astilbin through gastrointestinal protection, β‐glucanase‐responsive release, mucus penetration, and prolonged retention. The released astilbin attenuates senescence‐associated features of CD4+ T cells and promotes Treg responses, while the nanogel matrix modulates the gut ...
Lei Zhao +11 more
wiley +1 more source
Checkpoint‐directed glycoengineering installs sialylated ligands on the donor vascular lumen during ex vivo preservation, creating a localized Siglec‐7/9‐engaging interface. The engineered glycocalyx suppresses immune‐cell activation, complement deposition, and microvascular injury in arterial and kidney allografts while preserving endothelial ...
Md Mohosin Rana +19 more
wiley +1 more source
Bioengineered stroma‐camouflaged nanovesicles (AM@UIO‐BMS/DOX) convert the immunosuppressive tumor niche into an immunoresponsive milieu by disrupting the IDO1/CD276 circuit. Anti‐CD276 membrane camouflage guides tumor accumulation and deep penetration, enabling controlled co‐delivery of DOX and the IDO1 inhibitor BMS‐986205.
Ziqi Zhang +11 more
wiley +1 more source
Myocarditis With Immune Checkpoint Blockade [PDF]
In their discussion of fulminant myocarditis and complete heart block during immune checkpoint therapy, Johnson et al. do not discuss the possible role of circulating anticonductive tissue autoantibodies (ACTA) in the pathogenesis of the sudden heart block and myocarditis.1 Since it is not known which autoantigens (other than troponin I, which was ...
Javid J. Moslehi +2 more
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
The future of microfluidics in immune checkpoint blockade
Cancer Gene Therapy, 2020Recent advances in microfluidic techniques have enabled researchers to study sensitivities to immune checkpoint therapy, to determine patients' response to particular antibody treatment. Utilization of this technology is helpful in antibody discovery and in the design of personalized medicine.
Jonathan Briones +5 more
openaire +2 more sources
Immune Checkpoint Blockade in Malignant Mesothelioma
Seminars in Oncology, 2015Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient ...
Calabro' L, Maio M.
openaire +3 more sources
Combined Immune Checkpoint Blockade
Seminars in Oncology, 2015There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire +2 more sources

